Developing a Natural History Model for Duchenne Muscular Dystrophy.
Jonathan BroomfieldM HillF ChandlerM J CrowtherJ GodfreyM GuglieriJ HastieJ LarkindaleJ Mumby-CroftE ReubenF WoodcockK R Abramsnull nullPublished in: PharmacoEconomics - open (2023)
The model includes a detailed disease pathway for DMD, including the clinically and economically important transfer state. The NHM may be used to estimate the current trajectory of DMD in economic evaluations of new treatments, facilitating inclusion of a lifetime time horizon, and will help identify areas for further research.